Anteris Technologies GlobalAVR +0.81%23 ROC (Joel Greenblatt) % is -1,177.53% as of Mar. 2026. GuruFocus rates AVR with a GF Score™ of 23/100. The stock has 7 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 93.69% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Anteris Technologies Global's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,177.53%.
The historical rank and industry rank for Anteris Technologies Global's ROC (Joel Greenblatt) % or its related term are showing as below:
AVR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1435.79 Med: -706.57 Max: -166.91
Current: -1344.42
During the past 13 years, Anteris Technologies Global's highest ROC (Joel Greenblatt) % was -166.91%. The lowest was -1435.79%. And the median was -706.57%.
AVR's ROC (Joel Greenblatt) % is ranked worse than 93.69% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs AVR: -1344.42
Anteris Technologies Global (NAS:AVR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global ROC (Joel Greenblatt) % Chart
AVR vs QDEL, INMD, CNMD: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Anteris Technologies Global's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's ROC (Joel Greenblatt) % falls into.
Anteris Technologies Global ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,177.53% mean?
Anteris Technologies Global (AVR) has a ROC (Joel Greenblatt) % of -1,177.53% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #787 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 93.7%.
Is Anteris Technologies Global's ROC (Joel Greenblatt) % too high?
Anteris Technologies Global's current ROC (Joel Greenblatt) % is -1,177.53%. Based on the distribution chart, Anteris Technologies Global ranks #787 out of 840 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's ROC (Joel Greenblatt) % compare to QDEL and INMD?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #787 out of 840 companies for ROC (Joel Greenblatt) %. This places Anteris Technologies Global in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current ROC (Joel Greenblatt) % is -1,177.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (AVR) has a current ROC (Joel Greenblatt) % of -1,177.53%. The current ROC (Joel Greenblatt) % is -1,177.53%. Anteris Technologies Global's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Anteris Technologies Global (AVR), the current ROC (Joel Greenblatt) % is -1,177.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
23GF Score
Get the complete analysis for AVR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVR has been successfully added to your 
